NovaBridge Reports Positive Phase 1b Results for Givastomig

NovaBridge Biosciences announced positive updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy in patients with HER2-negative, first line metastatic gastric cancer. Key results: Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levels; The median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026; Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohorts; Combination was well tolerated; safety is comparable to the current standard of care treatment; Data demonstrate that givastomig is a potential best-in-class CLDN18.2 asset when added to 1L standard of care; NovaBridge is on track to initiate enrollment in a global, randomized Phase 2 study, evaluating both doses against standard of care, in Q1 2026; Detailed Phase 1b dose expansion data are expected to be presented at a medical conference later in 2026.